Forskning ved Københavns Universitet - Københavns Universitet

Forside

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. / Iversen, P; Tveter, K; Varenhorst, E.

I: Scandinavian Journal of Urology and Nephrology, Bind 30, Nr. 2, 1996, s. 93-8.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Iversen, P, Tveter, K & Varenhorst, E 1996, 'Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group', Scandinavian Journal of Urology and Nephrology, bind 30, nr. 2, s. 93-8.

APA

Iversen, P., Tveter, K., & Varenhorst, E. (1996). Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scandinavian Journal of Urology and Nephrology, 30(2), 93-8.

Vancouver

Iversen P, Tveter K, Varenhorst E. Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scandinavian Journal of Urology and Nephrology. 1996;30(2):93-8.

Author

Iversen, P ; Tveter, K ; Varenhorst, E. / Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. I: Scandinavian Journal of Urology and Nephrology. 1996 ; Bind 30, Nr. 2. s. 93-8.

Bibtex

@article{4ea56deafbf5492e90b1b80a2fc1e11c,
title = "Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group",
abstract = "The effect of Casodex (ICI 176,334), a new, once-daily, selective antiandrogen, given as 50 mg monotherapy, was compared with orchidectomy in a randomised, multicentre, open study in 376 patients with metastatic prostate cancer. At 3 months, PSA was reduced by 86{\%} in the Casodex group and by 96{\%} in the orchidectomy group. Treatment failed in 51 patients in the orchidectomy group and 66 showed a subjective response. Treatment failed in 86 patients treated with Casodex and 40 patients showed a subjective response. Patients treated with Casodex maintained their sexual interest better than those in the orchidectomy group. Median survival was significantly longer in the orchidectomy group. Casodex was well-tolerated. The most likely reason for the differences between the groups regarding time to treatment failure and survival is that the dose of Casodex was too small. Further studies with higher doses of Casodex are in progress.",
author = "P Iversen and K Tveter and E Varenhorst",
year = "1996",
language = "English",
volume = "30",
pages = "93--8",
journal = "Scandinavian Journal of Urology and Nephrology",
issn = "0036-5599",
publisher = "Taylor & Francis",
number = "2",

}

RIS

TY - JOUR

T1 - Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group

AU - Iversen, P

AU - Tveter, K

AU - Varenhorst, E

PY - 1996

Y1 - 1996

N2 - The effect of Casodex (ICI 176,334), a new, once-daily, selective antiandrogen, given as 50 mg monotherapy, was compared with orchidectomy in a randomised, multicentre, open study in 376 patients with metastatic prostate cancer. At 3 months, PSA was reduced by 86% in the Casodex group and by 96% in the orchidectomy group. Treatment failed in 51 patients in the orchidectomy group and 66 showed a subjective response. Treatment failed in 86 patients treated with Casodex and 40 patients showed a subjective response. Patients treated with Casodex maintained their sexual interest better than those in the orchidectomy group. Median survival was significantly longer in the orchidectomy group. Casodex was well-tolerated. The most likely reason for the differences between the groups regarding time to treatment failure and survival is that the dose of Casodex was too small. Further studies with higher doses of Casodex are in progress.

AB - The effect of Casodex (ICI 176,334), a new, once-daily, selective antiandrogen, given as 50 mg monotherapy, was compared with orchidectomy in a randomised, multicentre, open study in 376 patients with metastatic prostate cancer. At 3 months, PSA was reduced by 86% in the Casodex group and by 96% in the orchidectomy group. Treatment failed in 51 patients in the orchidectomy group and 66 showed a subjective response. Treatment failed in 86 patients treated with Casodex and 40 patients showed a subjective response. Patients treated with Casodex maintained their sexual interest better than those in the orchidectomy group. Median survival was significantly longer in the orchidectomy group. Casodex was well-tolerated. The most likely reason for the differences between the groups regarding time to treatment failure and survival is that the dose of Casodex was too small. Further studies with higher doses of Casodex are in progress.

M3 - Journal article

VL - 30

SP - 93

EP - 98

JO - Scandinavian Journal of Urology and Nephrology

JF - Scandinavian Journal of Urology and Nephrology

SN - 0036-5599

IS - 2

ER -

ID: 48470578